logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Melanoma

    FiltersReset Filters
    6 results

    • imlygic

      (talimogene laherparepvec)
      Amgen Inc
      Usage: IMLYGIC is indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma patients with recurrence after surgery. It does not improve overall survival or affect visceral metastases.

    • mekinist

      (trametinib)
      Novartis Pharmaceuticals Corporation
      Usage: MEKINIST is indicated for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, metastatic non-small cell lung cancer, anaplastic thyroid cancer, unresectable solid tumors, and low-grade glioma in pediatric patients, often in combination with dabrafenib. Not indicated for colorectal cancer.

    • opdivo

      (nivolumab)
      E.R. Squibb & Sons, L.L.C.
      Usage: OPDIVO is indicated for the treatment of various cancers, including unresectable/metastatic melanoma, neoadjuvant and adjuvant non-small cell lung cancer, metastatic non-small cell lung cancer, malignant pleural mesothelioma, advanced renal cell carcinoma, classical Hodgkin lymphoma, and others. It is used in different combinations and settings based on the cancer type.

    • opdualag

      (nivolumab and relatlimab-rmbw)
      E.R. Squibb & Sons, L.L.C.
      Usage: OPDUALAG™ is indicated for the treatment of adult and pediatric patients aged 12 and older with unresectable or metastatic melanoma.

    • tecentriq

      (atezolizumab)
      Genentech, Inc.
      Usage: TECENTRIQ is indicated for treating various cancers, including: non-small cell lung cancer (adjuvant and metastatic), extensive-stage small cell lung cancer, unresectable or metastatic hepatocellular carcinoma, BRAF V600 mutation-positive melanoma, and unresectable or metastatic alveolar soft part sarcoma.

    • tecentriq hybreza

      (atezolizumab and hyaluronidase-tqjs)
      Genentech, Inc.
      Usage: TECENTRIQ HYBREZA is indicated for treating various cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (ES-SCLC), unresectable or metastatic hepatocellular carcinoma (HCC), BRAF V600 mutation-positive melanoma, and unresectable or metastatic alveolar soft part sarcoma (ASPS) in adults.